| scholarly article | Q13442814 |
| P50 | author | Sohei Kitazawa | Q40295146 |
| P2093 | author name string | Hideki Fujii | |
| Fuyuhiko Nishijima | |||
| Mikio Sugano | |||
| Masafumi Fukagawa | |||
| Hideyuki Yamato | |||
| Riko Kitazawa | |||
| Sumie Goto | |||
| P2860 | cites work | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| Oxidants in chronic kidney disease | Q36682519 | ||
| Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity | Q39571547 | ||
| Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity | Q40721603 | ||
| Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake | Q40754117 | ||
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | Q43683472 | ||
| Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure | Q44091656 | ||
| Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity | Q44131325 | ||
| Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study | Q44137839 | ||
| High levels of myocardial antioxidant defense in aging nondiabetic normotensive Zucker obese rats | Q44689971 | ||
| Characterization of uremic toxin transport by organic anion transporters in the kidney | Q44692966 | ||
| Indoxyl sulfate induces complex redox alterations in mesangial cells | Q46910093 | ||
| Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. | Q53574044 | ||
| Prospective Randomized Study Evaluating the Efficacy of the Spherical Adsorptive Carbon AST-120 in Chronic Kidney Disease Patients with Moderate Decrease in Renal Function | Q57623289 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | charcoal | Q177463 |
| chronic renal insufficiency | Q736715 | ||
| activated carbon | Q190878 | ||
| P304 | page(s) | 2089-2095 | |
| P577 | publication date | 2009-02-02 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress | |
| P478 | volume | 24 |
| Q42682778 | Adjusted Anion Gap Is Associated with Glomerular Filtration Rate Decline in Chronic Kidney Disease |
| Q37084883 | Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction |
| Q36413018 | Apocynin improving cardiac remodeling in chronic renal failure disease is associated with up-regulation of epoxyeicosatrienoic acids |
| Q43461034 | Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease |
| Q60917395 | Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease |
| Q38218395 | Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins |
| Q26830674 | Cardiorenal syndrome: the emerging role of protein-bound uremic toxins |
| Q58773641 | Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome |
| Q89762306 | CharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function Deterioration |
| Q36099390 | Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients |
| Q89459610 | Echocardiography-based pressure-volume loop assessment in the evaluation for the effects of indoxyl sulfate on cardiovascular function |
| Q92935518 | Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease |
| Q91142496 | Evolving concepts in the pathogenesis of uraemic cardiomyopathy |
| Q104286628 | Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review |
| Q47214357 | Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques |
| Q39309486 | Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study |
| Q30497600 | Indoxyl Sulfate Induces Leukocyte-Endothelial Interactions through Up-regulation of E-selectin |
| Q42917319 | Indoxyl Sulfate Stimulates Monocyte Chemoattractant Protein-1 Expression in Human Umbilical Vein Endothelial Cells by Inducing Oxidative Stress Through Activation of the NADPH Oxidase-Nuclear Factor-.KAPPA.B Pathway |
| Q92800661 | Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance |
| Q39125093 | Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. |
| Q54513215 | Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress. |
| Q38951536 | Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis |
| Q103001939 | Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus |
| Q35798608 | Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. |
| Q93053761 | Intestinal microbiome and fitness in kidney disease |
| Q89989584 | Lactobacillus salivarius BP121 prevents cisplatin‑induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p‑cresol sulfate via alleviating dysbiosis |
| Q41025409 | Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study |
| Q37883149 | Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon |
| Q59808758 | Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia |
| Q42876598 | Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry |
| Q64885085 | Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016. |
| Q35466116 | Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice |
| Q38826236 | Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome |
| Q38190366 | Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients |
| Q37954338 | Protein-bound uremic toxins: new insight from clinical studies |
| Q39202218 | Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease |
| Q36836055 | Role of Indoxyl Sulfate as a Predisposing Factor for Atrial Fibrillation in Renal Dysfunction |
| Q55254641 | Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. |
| Q43467792 | Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. |
| Q53674702 | Rosiglitazone attenuates indoxyl sulphate-induced endothelial dysfunction. |
| Q37378435 | Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients |
| Q38128596 | Targeting protein-bound uremic toxins in chronic kidney disease |
| Q39186198 | Targeting the Microbiome in Heart Failure |
| Q64964312 | The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. |
| Q40117766 | The Loss of GSTM1 Associates with Kidney Failure and Heart Failure |
| Q52146506 | The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. |
| Q28382992 | The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease |
| Q92958030 | The gut microbiota and its interactions with cardiovascular disease |
| Q26795563 | The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective |
| Q90723728 | Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications |
| Q37855988 | Uremic toxins and oral adsorbents |
| Q30244334 | Uremic toxins: some thoughts on acrolein and spermine |
| Q39243739 | Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins. |
| Q84090882 | p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease |
Search more.